# Pharma Translation Platform: What to Require | Vitra.ai > Output quality is where every pharma vendor looks identical. Validation, traceability and terminology control are where they do not for most banks. **Canonical URL**: https://www.vitra.ai/pharmaceuticals/pharma-translation-platform **Source**: This is the Markdown rendering of https://www.vitra.ai/pharmaceuticals/pharma-translation-platform, generated at build time from that page. --- 3 min read # Pharma Translation Platform: What to Require Output quality is where every pharma vendor looks identical. Validation, traceability and terminology control are where they do not for most banks. [Samhitha J Bhatt](https://www.vitra.ai/author/samhitha) Senior Product Manager , Vitra.ai Updated Aug 17, 2026 ![Pharma Translation Platform: What to Require](https://www.vitra.ai/static/images/blog/pharma-translation-platform.jpg) Table of contents [The demo tells you nothing](#the-demo-tells-you-nothing) [The four requirements](#the-four-requirements) [Validation is the question behind all four](#validation-is-the-question-behind-all-four) [Format coverage matters more than in other industries](#format-coverage-matters-more-than-in-other-industries) [Where to start](#where-to-start) [FAQ](#faq) Contributors [Samhitha J Bhatt](https://www.vitra.ai/author/samhitha) Senior Product Manager Subscribe to our newsletter Subscribe > **Quick answer —** Require four things of a pharma translation platform: a generated audit trail, version binding to the source, enforced controlled vocabulary, and a deployment posture your quality function will accept. Output quality is not the differentiator. ## The demo tells you nothing Every vendor renders a patient leaflet well. None fails that test, and it is therefore not a test. What separates them is whether a quality assurance lead will sign off on the system itself, which is a different question asked by different people and usually asked too late. ## The four requirements **A generated [audit trail](https://www.vitra.ai/general/content-approval-workflow).** Not an export, not a report somebody assembles. The record of who approved what, when and against which source should be a by-product of doing the work. **Version binding.** Every translation tied to a source version, so an amendment marks its translations stale rather than leaving them silently wrong. **Enforced terminology.** Controlled vocabularies that the system refuses to improve. A glossary that a model can override is decoration. **A deployment posture quality will accept.** Where content is processed, what is retained, whether a validated environment is available. This decides the shortlist and it is rarely raised in the first meeting. ## Validation is the question behind all four A system touching regulated content may need qualifying. Ask what documentation the vendor supplies for that, because assembling it yourself costs more than the licence. ## Format coverage matters more than in other industries Labelling artwork, structured dossier modules, infographics, validated e-learning. A text-only tool covers a minority of pharma content, and [image translation](https://www.vitra.ai/features/image-translation) plus [document translation](https://www.vitra.ai/features/document-translation) is what closes the gap. ## Where to start Bring quality assurance into the first vendor meeting rather than the fourth. [AI for pharma](https://www.vitra.ai/pharmaceuticals/ai-for-pharmaceuticals) covers the content split. ## FAQ **What separates pharma translation platforms?** Not output quality, which is uniformly good. A generated audit trail, version binding to the source, enforced controlled vocabulary and an acceptable deployment posture are where they differ. **What makes an audit trail acceptable?** That it is generated rather than assembled. A record of who approved what, when and against which source version should be a by-product of the work, not an export somebody compiles afterwards. **Can a glossary be advisory in pharma?** No. A controlled vocabulary that a model is allowed to override is decoration. The system has to refuse improvements to MedDRA terms, international non-proprietary names and dosage forms. **When should quality assurance be involved in vendor selection?** In the first meeting rather than the fourth. Whether a quality lead will sign off on the system decides the shortlist, and raising it late wastes the whole evaluation. Our blog ## Lastest blog posts Tool and strategies modern teams need to help their companies grow. Automotive [Automotive Brochure Localization by Market](https://www.vitra.ai/automotive/automotive-brochure-localization) A car brochure is a spec grid, a legal footer and a photo library, all market-specific. What actually has to change, and why the layout decides the schedule. [Samhitha J Bhatt](https://www.vitra.ai/author/samhitha) Aug 18, 2026 Automotive [Automotive Campaign Localization Across Markets](https://www.vitra.ai/automotive/automotive-campaign-localization) Campaigns run through national companies and dealer networks, so one master becomes hundreds of files. Where the offer text and the disclaimers actually break. [Samhitha J Bhatt](https://www.vitra.ai/author/samhitha) Aug 18, 2026 Automotive [Car Service Manual Translation for Technicians](https://www.vitra.ai/automotive/automotive-service-manual-translation) A workshop manual is read mid-repair by someone with the car on a lift. What that demands of procedures, torque figures and fault codes, in every language. [Samhitha J Bhatt](https://www.vitra.ai/author/samhitha) Aug 18, 2026 [View all posts](https://www.vitra.ai/blog/page/1) --- ## Structured data ```json { "@context": "https://schema.org", "@type": "Article", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://www.vitra.ai/pharmaceuticals/pharma-translation-platform" }, "headline": "Pharma Translation Platform: What to Require", "image": [ { "@type": "ImageObject", "url": "https://www.vitra.ai/static/images/blog/pharma-translation-platform.jpg" } ], "datePublished": "2025-07-07T00:00:00.000Z", "dateModified": "2026-08-17T00:00:00.000Z", "author": [ { "@type": "Person", "name": "Samhitha J Bhatt" } ], "publisher": { "@type": "Organization", "name": "Vitra.ai", "logo": { "@type": "ImageObject", "url": "https://www.vitra.ai/static/images/vitra-v-logo.png" } }, "description": "Output quality is where every pharma vendor looks identical. Validation, traceability and terminology control are where they do not for most banks." } ``` ```json { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.vitra.ai" }, { "@type": "ListItem", "position": 2, "name": "Pharmaceuticals", "item": "https://www.vitra.ai/pharmaceuticals" }, { "@type": "ListItem", "position": 3, "name": "Pharma Translation Platform: What to Require", "item": "https://www.vitra.ai/pharmaceuticals/pharma-translation-platform" } ] } ``` ```json { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What separates pharma translation platforms?", "acceptedAnswer": { "@type": "Answer", "text": "Not output quality, which is uniformly good. A generated audit trail, version binding to the source, enforced controlled vocabulary and an acceptable deployment posture are where they differ." } }, { "@type": "Question", "name": "What makes an audit trail acceptable?", "acceptedAnswer": { "@type": "Answer", "text": "That it is generated rather than assembled. A record of who approved what, when and against which source version should be a by-product of the work, not an export somebody compiles afterwards." } }, { "@type": "Question", "name": "Can a glossary be advisory in pharma?", "acceptedAnswer": { "@type": "Answer", "text": "No. A controlled vocabulary that a model is allowed to override is decoration. The system has to refuse improvements to MedDRA terms, international non-proprietary names and dosage forms." } }, { "@type": "Question", "name": "When should quality assurance be involved in vendor selection?", "acceptedAnswer": { "@type": "Answer", "text": "In the first meeting rather than the fourth. Whether a quality lead will sign off on the system decides the shortlist, and raising it late wastes the whole evaluation." } } ] } ```